| dc.creator | Oleshchuk, O. M. | |
| dc.creator | Loi, H. Ya. | |
| dc.date | 2017-07-12 | |
| dc.date.accessioned | 2020-07-03T09:39:53Z | |
| dc.date.available | 2020-07-03T09:39:53Z | |
| dc.identifier | https://ojs.tdmu.edu.ua/index.php/ijmr/article/view/7563 | |
| dc.identifier | 10.11603/ijmmr.2413-6077.2017.1.7563 | |
| dc.identifier.uri | https://repository.tdmu.edu.ua/handle/123456789/16430 | |
| dc.description | Leptin is one of adipocyte-secreted hormones. It signals to the brain and other tissues about the status of body energy reserves. Circulating leptin levels are directly proportional to the amount of the body fat. Leptin concentration increases when surfeit and decreases during fasting. Obese patients are hyperleptinemic compared with thin persons and they are tolerant to the central hypothalamic effects of leptin. The reduced sensitivity toward exogenous and endogenous leptin is commonly referred to as leptin resistance. Alterations in the signaling of the long isoform of the leptin receptor play the crucial role in leptin resistance. Surfeit may induce leptin resistance and other metabolic sequelae of obesity. Leptin insensitivity and insulin resistance play a major role in the development of type 2 diabetes. Metformin remains the preferred first-line pharmacologic agent for the treatment of type 2 diabetes. It reduces hepatic glucose production, increases glucose uptake in peripheral tissue and can lead to weight loss. Metformin decreases both insulin and leptin concentration, restores the sensitivity to these hormones. But some studies have shown poor relationship between metformin action and leptin level. And the mechanism of metformin action on leptin resistance remains unclear. Thus, these issues should be studied as well as polymorphisms in genes encoding metformin action. | en-US |
| dc.format | application/pdf | |
| dc.language | eng | |
| dc.publisher | I. Horbachevsky Ternopil National Medical University | en-US |
| dc.relation | https://ojs.tdmu.edu.ua/index.php/ijmr/article/view/7563/7340 | |
| dc.source | International Journal of Medicine and Medical Research; Vol. 3 No. 1 (2017): International Journal of Medicine and Medical Research; 15-21 | en-US |
| dc.source | International Journal of Medicine and Medical Research; Том 3 № 1 (2017): International Journal of Medicine and Medical Research; 15-21 | ru-RU |
| dc.source | International Journal of Medicine and Medical Research; Том 3 № 1 (2017): International Journal of Medicine and Medical Research; 15-21 | uk-UA |
| dc.source | 2414-9985 | |
| dc.source | 2413-6077 | |
| dc.source | 10.11603/ijmmr.2413-6077.2017.1 | |
| dc.subject | lleptine resistance | en-US |
| dc.subject | type 2 diabetes | en-US |
| dc.subject | metformin. | en-US |
| dc.title | LEPTIN RESISTANCE AND TYPE 2 DIABETES | en-US |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
